metformin has been researched along with Carcinoma, Pancreatic Ductal in 36 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Obesity has been linked to a higher risk of pancreatic cancer." | 5.91 | Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023) |
| "Metformin use was not associated with overall survival in the complete analyses (HR = 1." | 5.56 | Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus. ( Carson, KR; Chang, SH; Drake, BF; Luo, S; Sanfilippo, KM; Thomas, TS; Toriola, AT, 2020) |
| "Metformin inhibited pancreatic cancer initiation, suppressed chronic pancreatitis-induced tumorigenesis, and showed promising therapeutic effect in PDAC." | 3.85 | Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. ( Cao, J; Chen, K; Cheng, L; Duan, W; Gao, L; Jiang, Z; Lei, M; Li, J; Ma, Q; Qian, W; Sun, L; Yan, B; Zhou, C, 2017) |
| " Here, we show that treatment of pancreatic ductal adenocarcinoma (PDAC) cells (PANC-1, MiaPaCa-2) with the isoquinoline alkaloid berberine (0." | 3.80 | Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. ( Eibl, G; Ming, M; Rozengurt, E; Sinnett-Smith, J; Soares, HP; Wang, J; Young, SH, 2014) |
| "Long-standing type 1 diabetes and type 2 diabetes increase the risk for this malignancy, but the cancer can also induce pancreatogenic, or type 3c, diabetes as well." | 2.49 | Diabetes and cancer: placing the association in perspective. ( Andersen, DK, 2013) |
| "Obesity has been linked to a higher risk of pancreatic cancer." | 1.91 | Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023) |
| "Metformin use was not associated with overall survival in the complete analyses (HR = 1." | 1.56 | Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus. ( Carson, KR; Chang, SH; Drake, BF; Luo, S; Sanfilippo, KM; Thomas, TS; Toriola, AT, 2020) |
| "Metformin has plausible direct and indirect anti-cancer properties against pancreatic adenocarcinoma cells." | 1.56 | An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases. ( Broadhurst, PJ; Hart, AR, 2020) |
| "Gemcitabine (GEM) has become the standard chemotherapy for PDAC; however, acquired resistance to GEM is a major challenge." | 1.51 | Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma. ( Kitagawa, Y; Suzuki, K; Suzuki, Y; Takeuchi, O, 2019) |
| "Metformin is a very frequently prescribed drug used to treat type II diabetes." | 1.48 | Metformin influences drug sensitivity in pancreatic cancer cells. ( Abrams, SL; Candido, S; Cervello, M; Cocco, L; Follo, MY; Gizak, A; Lertpiriyapong, K; Libra, M; Lombardi, P; Martelli, AM; McCubrey, JA; Montalto, G; Murata, RM; Rakus, D; Ratti, S; Rosalen, PL; Steelman, L; Suh, PG, 2018) |
| "Treatment with metformin also suppressed tumor growth, invasion and EMT in LSL‑KrasG12D/+, Trp53fl/+and Pdx1‑Cre (KPC) transgenic mice that harbor spontaneous pancreatic cancer." | 1.48 | Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. ( Cao, J; Chen, K; Cheng, L; Duan, W; Li, J; Li, X; Ma, J; Ma, Q; Qian, W; Qin, T; Xiao, Y; Zhou, C, 2018) |
| "Hypoglycemia is associated with local invasion and angiogenesis, whereas hyperglycemia promotes metastatic colonization." | 1.48 | Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. ( Akkan, J; Benitz, S; Bruns, P; Ceyhan, GO; Cheng, T; Friess, H; Hofmann, T; Huang, P; Jäger, C; Jastroch, M; Jian, Z; Kleeff, J; Kleigrewe, K; Kong, B; Lamp, D; Maeritz, N; Michalski, CW; Nie, S; Raulefs, S; Shen, S; Shi, K; Steiger, K; Zhang, Z; Zou, X, 2018) |
| "Metformin use was also associated with better OS (P = 0." | 1.43 | Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. ( Anderson, EM; Chang, DT; Koong, AC; Kozak, MM; Norton, JA; Pai, JS; Poultsides, GA; Visser, BC; von Eyben, R, 2016) |
| "Metformin (Met) is an approved antidiabetic drug currently being explored for repurposing in cancer treatment based on recent evidence of its apparent chemopreventive properties." | 1.43 | Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. ( Barrios, CS; Boyle, K; Cheng, G; Dwinell, MB; Hardy, M; Johnson, BD; Kalyanaraman, B; Lopez, M; McAllister, D; Ouari, O; Weber, JJ; Zielonka, J, 2016) |
| "Metformin is a commonly prescribed biguanide oral hypoglycemic used for the treatment of type II DM." | 1.43 | Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis. ( Amin, S; Aronson, A; Boffetta, P; Lin, J; Lucas, AL; Mhango, G; Wisnivesky, J, 2016) |
| "Metformin is a widely used glucose-lowering drug." | 1.42 | Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. ( Babykutty, S; Chen, I; Chin, SM; Deshpande, V; Fukumura, D; Hato, T; Incio, J; Jain, RK; Liu, H; Suboj, P; Vardam-Kaur, T, 2015) |
| "Pancreatic cancer is a disease with a dismal prognosis and treatment options are limited." | 1.38 | A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells. ( Funakoshi, A; Ikeda, N; Kawanami, T; Takiguchi, S, 2012) |
| "Metformin pretreatment completely abrogated insulin-induced potentiation of Ca(2+) signaling but did not interfere with the effect of GPCR agonists alone." | 1.35 | Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. ( Eibl, G; Kisfalvi, K; Rozengurt, E; Sinnett-Smith, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.78) | 29.6817 |
| 2010's | 25 (69.44) | 24.3611 |
| 2020's | 10 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Pretta, A | 2 |
| Ziranu, P | 2 |
| Giampieri, R | 2 |
| Donisi, C | 2 |
| Cimbro, E | 2 |
| Spanu, D | 2 |
| Lai, E | 2 |
| Pecci, F | 2 |
| Balconi, F | 2 |
| Lupi, A | 2 |
| Pozzari, M | 2 |
| Persano, M | 2 |
| Murgia, S | 2 |
| Pusceddu, V | 2 |
| Puzzoni, M | 2 |
| Berardi, R | 2 |
| Scartozzi, M | 2 |
| Wang, G | 1 |
| Gao, H | 1 |
| Dai, S | 1 |
| Li, M | 1 |
| Gao, Y | 1 |
| Yin, L | 1 |
| Zhang, K | 1 |
| Zhang, J | 1 |
| Jiang, K | 1 |
| Miao, Y | 1 |
| Lu, Z | 1 |
| Toriola, AT | 1 |
| Luo, S | 1 |
| Thomas, TS | 1 |
| Drake, BF | 1 |
| Chang, SH | 1 |
| Sanfilippo, KM | 1 |
| Carson, KR | 1 |
| Han, H | 1 |
| Hou, Y | 1 |
| Chen, X | 2 |
| Zhang, P | 1 |
| Kang, M | 1 |
| Jin, Q | 1 |
| Ji, J | 1 |
| Gao, M | 1 |
| Broadhurst, PJ | 2 |
| Hart, AR | 2 |
| Terasaki, F | 1 |
| Sugiura, T | 1 |
| Okamura, Y | 1 |
| Ito, T | 1 |
| Yamamoto, Y | 1 |
| Ashida, R | 1 |
| Ohgi, K | 1 |
| Uesaka, K | 1 |
| Alcalá, S | 1 |
| Sancho, P | 4 |
| Martinelli, P | 2 |
| Navarro, D | 1 |
| Pedrero, C | 1 |
| Martín-Hijano, L | 1 |
| Valle, S | 1 |
| Earl, J | 1 |
| Rodríguez-Serrano, M | 1 |
| Ruiz-Cañas, L | 1 |
| Rojas, K | 1 |
| Carrato, A | 1 |
| García-Bermejo, L | 1 |
| Fernández-Moreno, MÁ | 1 |
| Hermann, PC | 2 |
| Sainz, B | 2 |
| Liu, SH | 2 |
| Yu, J | 2 |
| Creeden, JF | 1 |
| Sutton, JM | 1 |
| Markowiak, S | 1 |
| Sanchez, R | 2 |
| Nemunaitis, J | 2 |
| Kalinoski, A | 1 |
| Zhang, JT | 1 |
| Damoiseaux, R | 1 |
| Erhardt, P | 1 |
| Brunicardi, FC | 2 |
| Eyres, M | 1 |
| Lanfredini, S | 1 |
| Xu, H | 1 |
| Burns, A | 1 |
| Blake, A | 1 |
| Willenbrock, F | 1 |
| Goldin, R | 1 |
| Hughes, D | 1 |
| Hughes, S | 1 |
| Thapa, A | 1 |
| Vavoulis, D | 1 |
| Hubert, A | 1 |
| D'Costa, Z | 1 |
| Sabbagh, A | 1 |
| Abraham, AG | 1 |
| Blancher, C | 1 |
| Jones, S | 1 |
| Verrill, C | 1 |
| Silva, M | 1 |
| Soonawalla, Z | 1 |
| Maughan, T | 1 |
| Schuh, A | 1 |
| Mukherjee, S | 1 |
| O'Neill, E | 1 |
| Eibl, G | 4 |
| Rozengurt, E | 6 |
| Chen, K | 4 |
| Qian, W | 3 |
| Jiang, Z | 3 |
| Cheng, L | 3 |
| Li, J | 5 |
| Sun, L | 2 |
| Zhou, C | 4 |
| Gao, L | 1 |
| Lei, M | 1 |
| Yan, B | 2 |
| Cao, J | 3 |
| Duan, W | 4 |
| Ma, Q | 4 |
| Sun, H | 1 |
| Zheng, C | 1 |
| Gao, J | 1 |
| Fu, Q | 1 |
| Hu, N | 1 |
| Shao, X | 1 |
| Zhou, Y | 1 |
| Xiong, J | 1 |
| Nie, K | 1 |
| Zhou, H | 1 |
| Shen, L | 1 |
| Fang, H | 1 |
| Lyu, J | 1 |
| Candido, S | 1 |
| Abrams, SL | 1 |
| Steelman, L | 1 |
| Lertpiriyapong, K | 1 |
| Martelli, AM | 1 |
| Cocco, L | 1 |
| Ratti, S | 1 |
| Follo, MY | 1 |
| Murata, RM | 1 |
| Rosalen, PL | 1 |
| Lombardi, P | 1 |
| Montalto, G | 1 |
| Cervello, M | 1 |
| Gizak, A | 1 |
| Rakus, D | 1 |
| Suh, PG | 1 |
| Libra, M | 1 |
| McCubrey, JA | 1 |
| Song, L | 1 |
| Guo, J | 1 |
| Chang, R | 1 |
| Peng, X | 1 |
| Xu, X | 1 |
| Zhan, X | 1 |
| Zhan, L | 1 |
| Chang, HH | 1 |
| Moro, A | 1 |
| Chou, CEN | 1 |
| Dawson, DW | 1 |
| French, S | 1 |
| Schmidt, AI | 1 |
| Sinnett-Smith, J | 5 |
| Hao, F | 1 |
| Hines, OJ | 1 |
| Qin, T | 1 |
| Xiao, Y | 1 |
| Li, X | 2 |
| Ma, J | 2 |
| Jian, Z | 1 |
| Cheng, T | 1 |
| Zhang, Z | 1 |
| Raulefs, S | 1 |
| Shi, K | 1 |
| Steiger, K | 1 |
| Maeritz, N | 1 |
| Kleigrewe, K | 1 |
| Hofmann, T | 1 |
| Benitz, S | 1 |
| Bruns, P | 1 |
| Lamp, D | 1 |
| Jastroch, M | 1 |
| Akkan, J | 1 |
| Jäger, C | 1 |
| Huang, P | 1 |
| Nie, S | 1 |
| Shen, S | 1 |
| Zou, X | 1 |
| Ceyhan, GO | 1 |
| Michalski, CW | 1 |
| Friess, H | 1 |
| Kleeff, J | 1 |
| Kong, B | 1 |
| Suzuki, K | 1 |
| Takeuchi, O | 1 |
| Suzuki, Y | 1 |
| Kitagawa, Y | 1 |
| Andersen, DK | 1 |
| Soares, HP | 2 |
| Ni, Y | 1 |
| Kisfalvi, K | 2 |
| Lonardo, E | 2 |
| Cioffi, M | 2 |
| Sanchez-Ripoll, Y | 1 |
| Trabulo, SM | 1 |
| Dorado, J | 1 |
| Balic, A | 1 |
| Hidalgo, M | 1 |
| Heeschen, C | 3 |
| Cañamero, M | 1 |
| Madriles, F | 1 |
| Michl, P | 1 |
| Gress, T | 1 |
| de Pascual, R | 1 |
| Gandia, L | 1 |
| Guerra, C | 1 |
| Barbacid, M | 1 |
| Wagner, M | 1 |
| Vieira, CR | 1 |
| Aicher, A | 1 |
| Real, FX | 1 |
| Ming, M | 1 |
| Wang, J | 1 |
| Young, SH | 1 |
| Crusz, S | 1 |
| Kozak, MM | 1 |
| Anderson, EM | 1 |
| von Eyben, R | 1 |
| Pai, JS | 1 |
| Poultsides, GA | 1 |
| Visser, BC | 1 |
| Norton, JA | 1 |
| Koong, AC | 1 |
| Chang, DT | 1 |
| Incio, J | 1 |
| Suboj, P | 1 |
| Chin, SM | 1 |
| Vardam-Kaur, T | 1 |
| Liu, H | 1 |
| Hato, T | 1 |
| Babykutty, S | 1 |
| Chen, I | 1 |
| Deshpande, V | 1 |
| Jain, RK | 1 |
| Fukumura, D | 1 |
| Zhou, G | 1 |
| Wang, A | 1 |
| Wu, J | 1 |
| Ricordi, C | 1 |
| Chaiteerakij, R | 1 |
| Petersen, GM | 1 |
| Bamlet, WR | 1 |
| Chaffee, KG | 1 |
| Zhen, DB | 1 |
| Burch, PA | 1 |
| Leof, ER | 1 |
| Roberts, LR | 1 |
| Oberg, AL | 1 |
| Cheng, G | 1 |
| Zielonka, J | 1 |
| Ouari, O | 1 |
| Lopez, M | 1 |
| McAllister, D | 1 |
| Boyle, K | 1 |
| Barrios, CS | 1 |
| Weber, JJ | 1 |
| Johnson, BD | 1 |
| Hardy, M | 1 |
| Dwinell, MB | 1 |
| Kalyanaraman, B | 1 |
| Amin, S | 1 |
| Mhango, G | 1 |
| Lin, J | 1 |
| Aronson, A | 1 |
| Wisnivesky, J | 1 |
| Boffetta, P | 1 |
| Lucas, AL | 1 |
| Lei, J | 1 |
| Xu, Q | 1 |
| Han, L | 1 |
| Wang, Z | 1 |
| Wu, Z | 1 |
| Wang, F | 1 |
| Wu, E | 1 |
| Ma, Z | 1 |
| Halbrook, CJ | 1 |
| Lyssiotis, CA | 1 |
| Kawanami, T | 1 |
| Takiguchi, S | 1 |
| Ikeda, N | 1 |
| Funakoshi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for metformin and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Metformin: review of epidemiology and mechanisms of action in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Humans; Hypoglycemic Agents; Metformin; Pancreas; Pancreatic Neoplasms | 2021 |
Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use.
Topics: Carcinoma, Pancreatic Ductal; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms; Proof of | 2018 |
Diabetes and cancer: placing the association in perspective.
Topics: Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Diabetes Complications | 2013 |
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cellular Reprogramming; Fluorodeoxyglucose F18; Glucose; Glutamine; Hu | 2017 |
32 other studies available for metformin and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice.
Topics: Animals; Carcinogenesis; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Extracellular Traps; Metfo | 2023 |
Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.
Topics: Aged; Black or African American; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Comorbidity; | 2020 |
Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; C | 2020 |
An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases.
Topics: Aged; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Cross-Sectional Studies; Fe | 2020 |
Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus.
Topics: Adult; Aged; Carcinoma, Pancreatic Ductal; Diabetes Complications; Female; Humans; Hypoglycemic Agen | 2020 |
ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity.
Topics: Carcinoma, Pancreatic Ductal; Cell Line; Cell Plasticity; Cell Transformation, Neoplastic; Cytokines | 2020 |
Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Digoxin; Drug Combinations; Drug Reposition | 2020 |
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Topics: 5-Methylcytosine; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Biomarkers | 2021 |
Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer.
Topics: Animals; Carcinogenesis; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Disease Models, Animal; Di | 2017 |
Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth.
Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Apoptosis; Carcinogenesis; Carcinoma, Pancreatic Du | 2018 |
Metformin influences drug sensitivity in pancreatic cancer cells.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Metform | 2018 |
LKB1 obliterates Snail stability and inhibits pancreatic cancer metastasis in response to metformin treatment.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell | 2018 |
Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.
Topics: Acyltransferases; Administration, Oral; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Chemo | 2018 |
Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.
Topics: Animals; Apoptosis; Autocrine Communication; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell M | 2018 |
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycyt | 2018 |
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core | 2018 |
Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine | 2019 |
Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
Topics: Antibiotics, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Ext | 2013 |
Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells.
Topics: Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease | 2013 |
Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Topics: Acinar Cells; alpha7 Nicotinic Acetylcholine Receptor; Animals; Carcinoma, Pancreatic Ductal; Cell D | 2014 |
Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells.
Topics: Acetyl-CoA Carboxylase; Adenocarcinoma; AMP-Activated Protein Kinases; Animals; Berberine; Carcinoma | 2014 |
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Female; Humans; Metformin; Mice; Mic | 2015 |
Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; California; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Fem | 2016 |
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Epithelial | 2015 |
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2 | 2016 |
Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Female; Humans; Male; | 2016 |
Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Proliferation; | 2016 |
Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Comorbidity; Diabetes Mellitus, Type 2; Femal | 2016 |
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 2017 |
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.
Topics: Animals; Calcium; Carcinoma, Pancreatic Ductal; Cell Proliferation; DNA Replication; Down-Regulation | 2009 |
A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |